Bovi-Shield IBR

Bovine Rhinotracheitis Vaccine

Modified Live Virus

This product has been shown to be effective for the vaccination of healthy, nonpregnant cattle against respiratory disease caused by infectious bovine rhinotracheitis (IBR) virus. A duration of immunity of at least 9 months has been demonstrated. For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov.

Bovi-Shield IBR may be administered to calves nursing pregnant cows provided their dams were vaccinated, according to label directions, with any Bovi-Shield GOLD^® FP^® or PregGuard^® GOLD FP vaccine within the past 12 months.

PRODUCT DESCRIPTION: Bovi-Shield IBR is a freeze-dried preparation of a modified live virus (MLV) strain of the IBR virus, plus a sterile diluent used to rehydrate the freeze-dried vaccine.

Directions For Use

General Directions: Vaccination of healthy, nonpregnant cattle is recommended. Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, mix well, and administer 2 mL subcutaneously or intramuscularly. In accordance with Beef Quality Assurance guidelines, this product should be administered SC in the neck region.

Primary Vaccination: Administer a single 2-mL dose to healthy cattle. The presence of maternal antibody is known to interfere with the development of active immunity in cattle and additional boosters will be required in most young animals.

Revaccination: Historically, annual revaccination with this product was recommended. The need for booster vaccinations has not been established for this product; consultation with a veterinarian or the manufacturer is recommended.

Good animal husbandry and herd health management practices should be employed.

Precautions

Do not use in pregnant cows (abortions can result). Do not use in calves nursing pregnant cows unless their dams were vaccinated, according to label directions, with any Bovi-Shield GOLD FP or PregGuard GOLD FP vaccine within the past 12 months.

Store at 2°-8°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.

Use entire contents when first opened.

Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.

Inactivate unused contents before disposal.

Do not vaccinate within 21 days before slaughter.

Contains gentamicin as preservative.

As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

Fetal health risks associated with vaccination of pregnant animals with modified live vaccines cannot be unequivocally determined by clinical trials conducted for licensure. Management strategies based on vaccination of pregnant animals with modified live vaccines should be discussed with a veterinarian.

Do not mix with other products, except as specified above.

In case of human exposure, contact a physician.

Technical inquiries should be directed to Zoetis Inc. Veterinary Services, (888) 963-8471.

This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

For veterinary use only

VLN 190/PCN 1101.21

Zoetis Inc., Kalamazoo, MI 49007, USA

51288901

Presentation: 50 dose vial.

CPN: 3690072.6